期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

维格列汀改善2型糖尿病患者B细胞功能的Meta分析 被引量：5

Improvement Effect of Vildagliptin on B-cell Function in Patients with Type 2 Diabetes:a Meta-analysis
原文传递
导出
摘要 目的:系统评价维格列汀在改善2型糖尿病患者B细胞功能方面的疗效。方法:计算机检索Cochrane图书馆、PubMed、EMBASE、CBM、VIP、CNKI数据库,对纳入的随机对照试验(RCT)进行质量评价,并用RevMan5.0软件进行Meta分析。结果:共纳入3个RCT,Meta分析结果显示:维格列汀组在改善2型糖尿病患者稳态模型的B细胞功能指数(HOMA-B)方面的疗效优于安慰剂组,差异有统计学意义[MD=11.80,95%C(I7.88,15.72),P<0.00001];而在改善稳态模型的胰岛素抵抗指数(HOMA-IR)方面,2组差异无统计学意义[MD=-0.25,95%C(I-0.68,0.18),P=0.25]。结论:维格列汀在改善B细胞功能方面有一定疗效,但在改善胰岛素耐受方面的疗效与安慰剂无统计学差异。但纳入研究随访时间较短,纳入患者人数较少,结论尚需日后有高质量、大样本、长期的试验进一步验证。 OBJECTIVE： To evaluate the effects of vildagliptin on B-cell function in type 2 diabetic patients. METHODS ： The Cochrane library, PubMed, EMBASE, CBM, VIP and CNKI databases were searched. Randomized controlled trails （RCTs） included were evaluated and analyzed by the RevMan 5.0 software. RESULTS： 3 RCTs were included. The result of Meta-analysis showed that： the improvement effect of vildagliptin on HOMA-B in type 2 diabetic patients was better than placbo, there was sig- nificant difference [MD=11.80, 95%CI（7.88, 15.72）,P〈0.000 01]. There was no statistical significance in the improvement of HOMA-IR between 2 groups [MD=0.25, 95%CI（-0.68, 0.18）,P=0.25]. CONCLUSION： Vildagliptin is effective in improving the HOMA-B, but the change in HOMA-IR is not significantly different between vildagliptin and placebo. High-quality large-scale long-term studies are needed to present evidence because of short time and few patients included.
作者 占美 吴逢波 黄晶 唐尧
机构地区 四川大学华西医院药剂科
出处 《中国药房》 CAS CSCD 2012年第6期555-557,共3页 China Pharmacy
关键词 维格列汀 2型糖尿病 B细胞 META分析 Vildagliptin Type 2 diabetes B-cell Meta-analysis
分类号 R977.15 [医药卫生—药品] R969.4 [医药卫生—药理学]
  • 相关文献

参考文献8

  • 1杜玲玲,安富荣.糖尿病治疗新药——利拉鲁肽[J].中国药房,2011,22(1):61-63. 被引量：9
  • 2World Health Organization.Definition, diagnosis and classification of diabetes mellitus and its complication[R]. WHO/NCD/NCS/, 1999: 31.
  • 3DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus[J]. Ann lntern Med, 1999,131 (4) : 281.
  • 4Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes[J]. J Clin Endocrinol Metab, 2005,90 (8) : 4 888.
  • 5Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 0. 2 [updated September 2009][DB]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
  • 6Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelveweek monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes [J]. Horm Metab Res,2006,38( 6 ) :423.
  • 7Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response [J]. Diabetes Obes Metab, 2005,7 (6) :692.
  • 8Kikuchi M, Haneda M, Koya D, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus[J]. Diabetes Res Clin Pract , 2010 , 89( 3 ) :216.

二级参考文献23

  • 1Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men[J]. Diabetologia, 2002, 45(2) : 195.
  • 2Degn KB, Juhl CB, Sturis J, et al. One week' s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211 ) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes[J]. Diabetes, 2004, 53(5):1 187.
  • 3Irie S, Matsumura Y, Zdravkovic M, et al. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose escalation study[J]. Int J Clin Pharmacol Ther, 2008, 46(6):273.
  • 4Kapitza C, Flint A, Spitzer H, et al. The effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide[J]. Diabetes, 2008, 57(S1):A593.
  • 5Bjomsdottir I, OlsenA, Larsen U, et al. Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptdyl peptidase Ⅳ and neutral endopeptidase[J]. Diabetologia, 2008, 51 ( S 1 ) : S356.
  • 6Helleberg H, Malm-Erjefalt M, Bjornsdottir I, et al. Metabolism and excretion of [Pal-3H]-liraglutide in human healthy subjects[J]. Diabetes, 2008, 57(S1) :A581.
  • 7Jacobsen LV, Hindsberger C, Robson R, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide[J]. Br J Clin Pharmacol, 2009 , 68 (6) :898.
  • 8Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide[J]. Diabetes, 2007, 56 (S1) :A145.
  • 9Malm-Erjefalt M, Ekblom M, Brondsted L, et al. A randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects [J]. Diabetes, 2008, 57 ( S 1 ) : A130.
  • 10Jacobsen LV, Brondsted L, Vouis J, et al. A randomized, double-blind, cross-over trial investigating the effect of liraglutide on the absorption of an oral contraceptive drug [J]. Diabetes, 2008, 57(S1) :A566.

共引文献8

同被引文献58

引证文献5

二级引证文献44

中国药房
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部